TG Therapeutics 皮下注射Briumvi耐受性良好,安全性特征与静脉剂型一致

美股速递
Jun 09

TG Therapeutics 公司宣布,其皮下注射剂型的Briumvi(ublituximab)在一项研究中普遍耐受性良好,其安全性特征与此前已获批准的静脉注射剂型保持一致。

这一积极数据进一步支持了Briumvi作为多发性硬化症治疗方案的潜力,并为患者提供了更便捷的给药选择。皮下注射方式有望缩短治疗时间,改善患者的治疗体验。公司将继续推进相关临床开发计划。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10